ALSO NOTED: Zogenix sells stock; Pharmasset shares jump on data; Seattle Genetics gains milestone; and much more...

> Zogenix has raised $18 million in a private placement of preferred stock. Release

> Shares of Pharmasset jumped earlier this week after the company announced positive data from an early stage study of R7128 in combination with Pegasys for chronic Hepatitis-C type 1. Report

> AtheroGenics has restructured $17.5 million of its 2008 convertible debt. Release

> Seattle Genetics has snared a $4 million milestone payment from Genentech. Release

> Researchers at UCLA have demonstrated how spinal cord injuries spur a natural ability to reorganize and restore cellular communication using alternative pathways in the nervous system. Report

> Scientists at MIT are reporting that the shape of structures in the avian flu virus closely match sugars found in the respiratory tracts of birds. Report

> A new pharma-funded study shows that lower copays equals higher adherence to drug regimens. The implications is that by spending some money up front on drugs for chronic diseases, companies might save in the long run on complications. Report

> The District of Columbia's governing council voted to require sales reps to obtain licenses, becoming the only jurisdiction in the country to do so. Report

And Finally... It's potential manna from heaven for statin makers: A new study shows the drugs may prevent cancer. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.